Welcome to our dedicated page for Pulmatrix news (Ticker: PULM), a resource for investors and traders seeking the latest updates and insights on Pulmatrix stock.
Pulmatrix, Inc. develops inhaled therapeutic product candidates using its iSPERSE dry powder delivery technology for migraine and respiratory diseases. Company news centers on clinical and regulatory disclosures tied to programs such as PUR3100, PUR1800 and PUR1900, along with operating results, corporate updates and financing or capital-structure matters.
Recurring developments also include material agreements, shareholder voting matters and governance disclosures that relate to Pulmatrix's public-company status and biopharmaceutical development activities.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Pulmatrix, Inc. (NASDAQ: PULM) announced its 2022 financial results and corporate updates on March 30, 2023. The company reported revenue of $6.1 million, a 17% increase from $5.2 million in 2021, driven by collaborations. The year-end cash position stood at $35.6 million, providing a runway into Q2 2024. Significant milestones include the initiation of a Phase 2b study for PUR1900, with the first patient dosed in Q1 2023, and successful topline results for the Phase 1 study of PUR3100, showing promising safety and efficacy data. The company aims for further clinical studies for both PUR1900 and PUR3100.
Pulmatrix, Inc. (NASDAQ: PULM) announced the dosing of the first patient in a Phase 2b clinical trial for PUR1900, an inhaled treatment for Allergic Bronchopulmonary Aspergillosis (ABPA) and asthma. This double-blind, placebo-controlled study will assess the safety and efficacy of PUR1900 over 16 weeks, followed by an 8-week observation period. The trial aims to enroll 30 subjects across the U.S., U.K., Australia, and France. This milestone supports Pulmatrix's collaboration with Cipla and targets proof-of-concept data by mid-2024, potentially establishing PUR1900 as the first approved treatment for ABPA.
Pulmatrix, Inc. (NASDAQ: PULM) announces a virtual key opinion leader (KOL) event titled "PUR3100 for the Treatment of Acute Migraine: Unlocking Potential of DHE Treatment" on February 3, 2023, at 10:00 AM ET. The event features Dr. Stewart J. Tepper from Dartmouth College, discussing the treatment landscape for migraine patients and the clinical profile of dihydroergotamine (DHE). Dr. Margaret Wasilewski, CMO of Pulmatrix, will present recent Phase 1 data on PUR3100, an orally inhaled DHE delivered via Pulmatrix's patented iSPERSE™ technology. The event will include a live Q&A session.